Secondary research

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, January 30, 2023
Beauficel-en-Lyons, Novartis, Public health, Immunology, Claude Bernard University Lyon 1, Urinary tract infection, OXFORD, Hepatitis B, Merck Serono, Cancer, CSO, Novartis Institute for Tropical Diseases, Vaccine, Infection, Roche, Scripps Research, Secondary research, ISCB Senior Scientist Award, Drug discovery, Biomedical Research, Autoimmunity, Doctor of Philosophy, Inflammation, Medical device, Science, Genetics, Vaccitech

“We are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,” said Chief Executive Officer, Bill Enright.

Key Points: 
  • “We are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,” said Chief Executive Officer, Bill Enright.
  • “Dr.
  • “For the past six years, Tom has been integral in elevating Vaccitech’s profile and pipeline to serve a global patient community.
  • Dr. Pelletier brings extensive experience to Vaccitech in the areas of immunology, inflammation and infectious diseases.

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023
Infection, NSCLC, Large-cell lung carcinoma, Secondary research, Pneumonia, Survival rate, Centre for Genomic Regulation, Union, Toxicity, Respiratory tract, Nature Biotechnology, Lluch, H2020, IRB, European Research Council, Lung cancer, Public health, Microbiology, Biotechnology, Biofilm, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, VAP, CRG, Research, Pseudomonas aeruginosa, Lung, Bacteria, Degenerative disease, Immune system, Survival, Patient, Engineering, Mouse, Mortality, European Innovation Council, Synthetic biology, Catalonia, Ventilator-associated pneumonia, Asthma, Enzyme, Inflammation, Doctor of Philosophy, Institute for Research in Biomedicine, Pharmaceutical industry, Vaccine, Science

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.

The FDA Further Expands Collaboration With CN Bio to Evaluate the PhysioMimix Multi-Organ Microphysiological System

Retrieved on: 
Tuesday, January 17, 2023
Pharmaceutical, Science, Health, Research, IND, System, Toxicity, Tissue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, CN, Drug development, Partnership, A, Food, Metabolism, OOC, Liver, Human, Disulfiram-like drug, MPS, Secondary research, Multi, Pharmaceutical industry, Medical device, Rubiano

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ MPS and their applications using the PhysioMimix™ Multi-organ System.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ MPS and their applications using the PhysioMimix™ Multi-organ System.
  • For orally administered drugs, a critical parameter that needs to be understood by drug developers and regulatory agencies is bioavailability.
  • Dr Emily Richardson, Lead Scientist at CN Bio, said: “We are extremely pleased with the FDA’s decision to deepen our research collaboration into the multi-organ space.
  • Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.

Myrtelle and rAAVen Therapeutics to Develop Novel Gene Therapy Vectors

Retrieved on: 
Wednesday, January 11, 2023
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Inc., Myrtelle Canavan, Therapy, AAV, CNS, Rita Raave, Partnership, Nervous system, Central nervous system, Neuroscience, Canavan disease, Neuron, Research, Disorder, Doctor of Philosophy, Secondary research, Neurodegeneration, Vaccine, Pharmacology

Myrtelle Inc. , (“Myrtelle”) a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and rAAVen Therapeutics , (“rAAVen”) an AAV engineering company focused on generating innovative vectors for the next generation of gene therapies, today announced a partnership to develop novel recombinant adeno-associated virus (“rAAV”) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.

Key Points: 
  • Myrtelle Inc. , (“Myrtelle”) a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and rAAVen Therapeutics , (“rAAVen”) an AAV engineering company focused on generating innovative vectors for the next generation of gene therapies, today announced a partnership to develop novel recombinant adeno-associated virus (“rAAV”) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.
  • When myelin is damaged or does not develop normally, these impulses slow down and affect normal brain function.
  • Myrtelle will test the vectors in a range of myelin-based disorders and, if successful, pursue further development.
  • “We appreciate the opportunity to help Myrtelle achieve their goals for their novel gene therapy programs.

New to The Street TV Announces Five Corporate Interviews on its 423rd Show Airing on the Fox Business Network, Tonight, Monday, January 09, 2023, at 10:30 PM PT

Retrieved on: 
Monday, January 9, 2023
FMW, Host, IOS, 2009 United Nations Climate Change Conference, Interview, CSE, Nasdaq MarketSite, Conference, Marketing, Therapy, Privacy, Cat, Bank, Acquisition, Animal, SMB, Corporation, Ford Motor Company, Social media, Data mining, Lightning, Dog, FRA, Water, Superior, Android, Veterinarian, Soil, VRM, NYSE, CCW, Limp, OTCQX, Research report, App Store (iOS/iPadOS), Blue Cruise, Nutrient, Horse, AC, Secondary research, EV, Television presenter, Ecology, Communication, Rehabilitation, PROMO, Non-fungible token, Osteoarthritis, MWI, Atmosphere, FRC, Electricity, Television, Mobile phone, Kellie, Upstream, Street, Abbie Hoffman: American Rebel

New to The Street's 423rd TV show line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's 423rd TV show line-up features the following five (5) Corporate interviews:
    1).
  • Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.
  • After multi-years in development, the F-150 Lightning came to the automotive marketplace, now completely sold out.
  • The Lightning comes with the Ford Blue Cruise feature that offers hands-free driving and self-adapting to road conditions when activated.

New to The Street / Newsmax TV Announces its Five Corporate Interviews for this Week's Broadcast, Saturday, January 7, 2023, Airing 3:30 PM ET

Retrieved on: 
Friday, January 6, 2023
Cat, Horse, Ecology, Veterinarian, Blue Cruise, Dog, Lightning, Host, Bank, Corporation, Soil, Ford Motor Company, MWI, IOS, Animal, Limp, OTCQX, Privacy, CSE, Rehabilitation, Nutrient, Atmosphere, Interview, Lighting, FRA, PROMO, Newsmax TV, Communication, EV, Water, AC, Superior, Non-fungible token, Acquisition, Research report, NYSE, 2009 United Nations Climate Change Conference, Android, Secondary research, Therapy, VRM, Osteoarthritis, Television presenter, Data mining, Social media, App Store (iOS/iPadOS), FRC, CCW, Electricity, Conference, Nasdaq MarketSite, SMB, Marketing, Television, Mobile phone, Abbie Hoffman: American Rebel, Street, Kellie, Upstream

Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.

Key Points: 
  • Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.
  • Ford Motor Company’s Jasen Turnbull, F-150 Lightning Marketing Manager, sits with Laura Reynolds, CarPro Automotive Reporter, and Jane King, TV Host at New to The Street .
  • The Lightning comes with the Ford Blue Cruise feature that offers hands-free driving and self-adapting to road conditions when activated.
  • New to The Street ‘s TV Host Jane King interviews Andy Ross, Chairman/CEO of America Rebel, Inc. (NASDAQ: AREB) ($AREB).

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

Retrieved on: 
Thursday, January 5, 2023
Secondary research, AbbVie, Patient, Biology, Partnership, Frontier, Proteome, E3, Precision medicine, SAN, Therapy, Pharmaceutical industry

These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform.

Key Points: 
  • These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform.
  • "Our collaboration with Frontier is continuing to make progress against difficult-to-drug protein targets," said Jonathon Sedgwick, Ph.D., vice president and global head, Discovery Research, AbbVie.
  • Started in 2020, the objective of the global partnership is to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
  • "Our delivery of three programs into lead generation further validates The Frontier™ Platform's ability to systematically discover and deliver small molecules to drug undruggable targets.

New to The Street Airs Episode #418, Five Corporate Interviews, Broadcasting on the Fox Business Network, Tonight, Monday, December 19, 2022, at 10:30 PM PT

Retrieved on: 
Monday, December 19, 2022
Ecology, Telehealth, FMW, Sensation, Smell, Growth, DVLP, Soil, Big Tech, JV, OTCQX, Privacy, CSE, Nutrient, Atmosphere, Health, Interview, 2020 Indian agriculture acts, High Sierra, FRA, Water, Superior, Acquisition, 2009 United Nations Climate Change Conference, Secondary research, Street, Patent, VRM, Television presenter, Cannabis, Garden, Third party, Smokeless tobacco, Social media, Hemp, Smoking, FRC, CCW, Tobacco industry, Patient, CBD, Relaxation, 418th, Internet, Conference, SHOT, Marketing, Television, Tobacco, Abbie Hoffman: American Rebel, Kellie

Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.

Key Points: 
  • Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.
  • Tonight, New to The Street airs TV Host Jane King's Nasdaq MarketSite studio interview with VRM BioLogik Group’s Founder, Ken Bellamy, and CEO, Kellie Walters.
  • From the air, one can see the improved soil composition compared to the surrounding desert, capable of growing crops.
  • As featured guests and keynote speakers, VRM explains the business collaboration and relationship between VRM and SGTM .

James G. Krueger MD, Ph.D., is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 29, 2022
Inflammatory bowel disease, Internal medicine, Pharmacogenomics, Rockefeller University, Hidradenitis suppurativa, Trial of the century, Patient, Psoriasis, Education, Continental, Cooking, Laboratory, Tissue, Immune system, Pinnacle, Innovation, Rheumatoid arthritis, Knowledge, Skin, Diagnosis, Cell biology, T helper 17 cell, Medicine, Inflammation, Degenerative disease, Weill Cornell Medicine, Gene expression, Bachelor, Therapy, Secondary research, Head, Science, American Board of Dermatology, Physician, Research, ABD, Princeton University, American Board of Commissioners for Foreign Missions, Vaccine, Pharmaceutical industry, Dermatology, Virology

NEW YORK, Dec. 29, 2022 /PRNewswire/ -- James G. Krueger MD, Ph.D., is being recognized by Continental Who's Who as a Top Pinnacle Member for his excellence as a Dermatologist at Rockefeller University Hospital.

Key Points: 
  • NEW YORK, Dec. 29, 2022 /PRNewswire/ -- James G. Krueger MD, Ph.D., is being recognized by Continental Who's Who as a Top Pinnacle Member for his excellence as a Dermatologist at Rockefeller University Hospital.
  • Dr. Krueger earned his Bachelor's degree from Princeton University and a Ph.D. in Virology and Cell Biology from Rockefeller University.
  • Dr. Krueger uses psoriasis as a model to study inflammatory diseases that involve Th17 cells, a set of T cells.
  • According to Dr. Krueger, the laboratory conducts clinical research on patients with psoriasis vulgaris at The Rockefeller University Hospital.

Leading TechBio Investment Firm ARTIS Ventures Announces 2022 Class of Healthcare and Life Sciences Fellows

Retrieved on: 
Wednesday, December 14, 2022
Immunotherapy, Lab, Pioneer, Synthetic biology, Secondary research, Stanford University, Modern Meadow, Drug discovery, Frances Raday, Family, National university, Fellows, University, DNA, MIT, Plastic and Reconstructive Surgery, Ecosystem, PhD-MBA, Doctor of Philosophy, Machine learning, MD, Johns Hopkins, National University of Singapore, Harvard University, AV, Investment, Biology, Developmental biology, University of California, San Diego, Memorial to Pioneer Odd Fellows, Medicine, Management, Fine chemical, AbbVie, Cohesity

San Francisco , Dec. 14, 2022 (GLOBE NEWSWIRE) -- ARTIS Ventures , a leading venture firm pioneering investments in the TechBio space, today announced its newest class of AV Fellows .

Key Points: 
  • San Francisco , Dec. 14, 2022 (GLOBE NEWSWIRE) -- ARTIS Ventures , a leading venture firm pioneering investments in the TechBio space, today announced its newest class of AV Fellows .
  • “At ARTIS, we partner with companies where we believe we can do our part to help them advance healthcare and biology beyond just financial support,” said Vasudev Bailey, PhD , senior partner at ARTIS Ventures.
  • “The breadth of experience that our Pioneers and Fellows bring to the ARTIS family is immeasurable,” said Stuart Peterson, managing partner of ARTIS.
  • As an early leader in the emerging TechBio sector , ARTIS Ventures funds companies at the intersection of computer science and life science, applying engineering principles and data-enabled discovery to the healthcare space.